SVB Securities analyst David Risinger reiterated a Buy rating on Theravance Biopharma (TBPH – Research Report) on February 28 and set a price target of $14.00. The company’s shares closed yesterday at $10.11.
Risinger covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Amgen, and Pfizer. According to TipRanks, Risinger has an average return of 3.4% and a 49.22% success rate on recommended stocks.
Theravance Biopharma has an analyst consensus of Moderate Buy, with a price target consensus of $14.00, a 38.48% upside from current levels. In a report released on February 28, H.C. Wainwright also reiterated a Buy rating on the stock with a $19.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $11.83 and a one-year low of $7.53. Currently, Theravance Biopharma has an average volume of 477.7K.
Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TBPH in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Theravance Biopharma, Inc. operates as a biopharmaceutical company. It focuses on the discovery, research, development, and commercialization of organ-selective medicines. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.
Read More on TBPH:
